Sanofi India Limited reported a steady financial performance for the quarter ended March 31, 2026, driven by the strong growth of its insulin portfolio. The company achieved ₹4,723 million in revenue from operations. Alongside the financial results, the board announced key leadership changes, including the appointment of Mr. Rahul Bhatnagar as Chairman of the Board, effective April 30, 2026, following the completion of tenure for two long-standing independent directors.
Financial Performance Highlights
For the quarter ended March 31, 2026, Sanofi India posted revenue from operations of ₹4,723 million. The company reported a profit for the period of ₹1,026 million. The insulin portfolio remains a key growth driver, achieving double-digit growth compared to the previous quarter and the corresponding period last year. Management attributed this success to the company’s established equity in the diabetes injectable segment and strong performance in the domestic market.
Strategic Leadership Changes
The company announced significant changes to its Board of Directors. Mr. Aditya Narayan and Mrs. Usha Thorat will step down as Independent Directors at the close of business on April 29, 2026. The Board expressed its appreciation for their contributions during their tenure.
Effective April 30, 2026, Mr. Rahul Bhatnagar has been appointed as the new Chairman of the Board. Furthermore, the company has reconstituted several key committees, including the Audit, Nomination and Remuneration, Stakeholders Relationship, Risk Management, and Corporate Social Responsibility committees to ensure robust governance and oversight.
Operational Focus
Despite the impact of partnership transitions on overall quarterly results, the company continues to focus on operational excellence. Sanofi remains committed to its strategy of driving efficiency through targeted market initiatives and refined go-to-market strategies. The organization continues to leverage its domestic manufacturing capabilities and global partnerships to maintain its position in the healthcare sector.
Source: BSE
